Researchers hope their novel tumor-buster is pure gold in more ways than one

Stanford biologists and engineers are working with gold nanoparticles to identify tumor margins practically down to the level of the individual cell.

According to an article from the school’s news office, the team has successfully tested the PET/CT technique in mice.

“In the lab we're now getting to a point where we can actually start asking these cancer cells real questions, like, for example, are you responding to the treatment we're giving you or not?” says Adam de la Zerda, PhD, whose work is inspired in part by the loss of a friend to brain cancer.

Read the piece: 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.